Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Brainstorm Cell Therapeutics Inc (BCLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BCLI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.68
1 Year Target Price $20.68
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.58% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.90M USD | Price to earnings Ratio - | 1Y Target Price 20.68 |
Price to earnings Ratio - | 1Y Target Price 20.68 | ||
Volume (30-day avg) 1 | Beta 0.11 | 52 Weeks Range 0.52 - 6.00 | Updated Date 08/14/2025 |
52 Weeks Range 0.52 - 6.00 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -222.36% | Return on Equity (TTM) -1121.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6580291 | Price to Sales(TTM) - |
Enterprise Value 6580291 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.7 | Shares Outstanding 9838860 | Shares Floating 6743440 |
Shares Outstanding 9838860 | Shares Floating 6743440 | ||
Percent Insiders 15.58 | Percent Institutions 13.63 |
Upturn AI SWOT
Brainstorm Cell Therapeutics Inc
Company Overview
History and Background
Brainstorm Cell Therapeutics Inc. was founded in 2003. It is a biotechnology company focused on developing innovative, autologous adult stem cell therapies for highly debilitating neurodegenerative diseases.
Core Business Areas
- NurOwn: Developing NurOwn (MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS).
Leadership and Structure
Chaim Lebovits is the CEO. The company has a board of directors overseeing its operations and a management team leading its research and development efforts.
Top Products and Market Share
Key Offerings
- NurOwn: NurOwn (MSC-NTF cells) is Brainstorm's lead investigational product, currently under regulatory review for ALS. Market share data is not applicable as it is not yet approved. Competitors for ALS treatment include Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio), and Mitsubishi Tanabe Pharma (Radicava).
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving. It focuses on developing new therapies for unmet medical needs.
Positioning
Brainstorm is positioned as a company developing novel cell therapies for neurodegenerative diseases. Its competitive advantage lies in its NurOwn technology.
Total Addressable Market (TAM)
The global ALS market is estimated to be several billion dollars. Brainstorm is positioning NurOwn to capture a portion of this market, contingent on regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel cell therapy technology (NurOwn)
- Experienced management team
- Strong intellectual property portfolio
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on regulatory approval
- Single lead product
- High cash burn rate
Opportunities
- Potential regulatory approval for NurOwn
- Expansion of NurOwn to other indications (e.g., MS)
- Partnerships with larger pharmaceutical companies
- Advancements in cell therapy technology
Threats
- Regulatory hurdles
- Competition from other therapies
- Clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- BIIB
- AMLY
- MTLHF
Competitive Landscape
Brainstorm faces significant competition from established pharmaceutical companies with approved ALS treatments. Its advantage is in its novel cell therapy approach, but it carries higher risk due to the unproven nature of the technology.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in R&D spending and clinical trial progress.
Future Projections: Future growth depends heavily on NurOwn regulatory approval. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include completion of clinical trials and submission of data to the FDA.
Summary
Brainstorm Cell Therapeutics is a high-risk, high-reward biotechnology company focused on developing NurOwn for neurodegenerative diseases. Its success is contingent upon regulatory approval, which is its primary challenge. The company is pioneering a novel cell therapy approach, offering potential advantages over existing treatments, but faces strong competition and financial constraints. Investment in Brainstorm is highly speculative and depends on a positive regulatory outcome for NurOwn.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (FactSet, Bloomberg)
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be outdated. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Brainstorm Cell Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2003-08-28 | President & CEO Mr. Chaim Lebovits | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://www.brainstorm-cell.com |
Full time employees 29 | Website https://www.brainstorm-cell.com | ||
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.